Berkeley Lights launches Opto Plasma B Discovery 4.0 workflow

By The Science Advisory Board staff writers

January 12, 2021 -- Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.

According to the company, the workflow can screen up to 100,000 cells and functionally test cells with highly sensitive cell-based assays. The workflow captures reexpressed molecules without the need for gene synthesis and bacterial cloning and increases the possibilities of success to access hard-to-hit targets.

The workflow uses the company's OptoSeq barcoded B-cell receptors, heavy and light chain antibody genes can be sequenced by DNA fragmentation, next-generation sequencing, and/or bioinformatics analysis. The results from the workflow can be integrated on the Berkeley Lights system to further accelerate candidates to market with antibody engineering and cell line development.

Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with...
Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...
Berkeley Lights debuts new workflow for Opto CLD
Berkeley Lights has introduced Opto Cell Line Development (CLD) 2.0, a new workflow designed for the Beacon optofluidic instrument.
Berkeley Lights launches Culture Station for faster cell processing
Berkeley Lights has announced the launch of Culture Station, a modular cell culture instrument that increases workflow capacity of optofluidic platforms,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter